Q2 2023 registration for the 340B program starts April 1 and is expected to end April 17.
The second quarterly period this year for 340B registration of new covered entities, outpatient facilities, and contract pharmacies will begin Saturday, April 1, and is expected to end on Monday, April 17.
CMS on Tuesday announced the first 27 prescription drugs that will be subject to Medicare Part B inflation rebates, and on Wednesday released guidance on the new Medicare drug price negotiation program—including its intersection with 340B.
The U.S. Centers for Medicare & Medicaid Services Tuesday announced the first 27 prescription drugs that will be subject to Medicare Part B inflation rebates, a list that includes AbbVie’s blockbuster arthritis drug Humira, which generated $5.6 billion
Amneal Pharmaceuticals is offering refunds for 340B overcharges on an 18-page-long list of products for purchases between Q3 2019 and Q3 2022.
Generic and specialty drug manufacturer Amneal Pharmaceuticals is offering refunds for 340B overcharges on an 18-page-long list of products for purchases between Q3 2019 and Q3 2022.
The U.S. Health Resources and Services Administration posted New Jersey-based Amneal’s
Lilly's decision to cut the price of its fast-acting insulin Humalog might have been driven by a desire to avoid exposure to Medicaid rebates, drug pricing expert Sean Dickson says.
Drug manufacturer Lilly’s announcement last week that it is slashing the price of Humalog, its most commonly prescribed insulin, may have been less about altruism and more about avoiding exposure to bigger Medicaid rebates, a prominent drug pricing
Zydus Pharmaceuticals is providing refunds for 340B overcharges during 2022 on 83 NDCs.
Generic drug manufacturer Zydus Pharmaceuticals USA said in a recent public notice it will pay refunds for 340B overcharges that occurred mostly in the first two quarters of 2022. The products include Zydus’ equivalents of the widely prescribed
HRSA has sent multiple hospitals letters asking about patient eligibility for 340B drugs, use of 340B savings, and 340B compliance in offsite outpatient locations.
UPDATED Thursday March 2, 2023, 12:30 p.m. EDT to include comment from HRSA.
The U.S. Health Resources and Services Administration has asked multiple hospitals to explain how they determine patient eligibility for 340B drugs, how they define, track,
IQVIA questions whether 340B claims identifiers can be used successfully to implement the Inflation Reduction Act's Medicare drug price negotiation and drug inflation rebate provisions.
New research by drug industry contractor IQVIA questions whether claims identifiers can be used successfully to exclude 340B-purchased drugs from new Medicare drug inflation rebates or to protect manufacturers from paying both a new negotiated Medicare price and
America’s Essential Hospitals wants HHS “to swiftly remedy five years of unlawful drug reimbursement cuts to 340B hospitals under Medicare Part B.”
America’s Essential Hospitals asked U.S. Health and Human Services Secretary Xavier Becerra late last week “to swiftly remedy five years of unlawful drug reimbursement cuts to 340B hospitals under Medicare Part B.”
CMS is seeking comment on how best to exclude 340B drugs from new Part D inflation rebate invoices.
The U.S. Centers for Medicare & Medicaid Services is seeking comments by March 11 on “the most reliable way to identify” 340B-purchased drugs dispensed to Medicare Part D beneficiaries so they can be excluded from new Part D
HHS OIG says CMS should monitor non-hospital covered entities' use of 340B modifiers when submitting Part B claims.
The U.S. Department of Health and Human Services Office of the Inspector General says the Centers for Medicare and Medicaid Services should monitor non-hospital 340B covered entities’ use of modifiers to identify 340B-priced drugs in Part B claims,
